Drug Interactions between delgocitinib topical and Sprycel

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Coadministration of topical delgocitinib with other Janus Kinase (JAK) inhibitors, biologic immunomodulators, or other potent immunosuppressants (e.g., cyclosporine, azathioprine) may potentiate the risk of infections as well as lymphoma and other malignancies. Serious and sometimes fatal infections including bacterial, mycobacterial (e.g., tuberculosis), fungal, viral including viral reactivation, and other opportunistic infections have been reported in patients who have received oral or topical JAK inhibitors. For example, in a follow-up open-label extension study in patients who received topical delgocitinib for 36 weeks (n= 801), cases of eczema herpeticum and herpes zoster were reported. However, the clinical relevance remains uncertain, as the bioavailability of topically applied delgocitinib is only about 0.6% compared to the oral route, resulting in low systemic absorption.

MANAGEMENT: Until further information is available, the concomitant use of topical delgocitinib with other Janus Kinase (JAK) inhibitors, biologic immunomodulators, or other potent immunosuppressants (e.g., cyclosporine, azathioprine) should be avoided. Patients receiving topical delgocitinib should be closely monitored for the development of signs and symptoms of infection during and after treatment. If a patient develops a serious infection, topical delgocitinib therapy should be interrupted until the infection is controlled.